Addison's Disease Market 2020-2026
Global Addison's Disease Market Size, Share & Trends Analysis Report by Diagnosis (Laboratory Testing and Imaging Tests), By Treatment (Oral Corticosteroid and Corticosteroid Injections), By End User (Hospitals and Clinics, and Diagnostic Laboratories) Forecast 2021-2027
The global market for Addison's disease is projected to have a considerable CAGR during the forecast period. Addison's disease, which is also known as adrenal insufficiency, is a disorder that occurs due to a lack of enough production of certain hormones (chemicals that control the function of tissues or organs.). In Addison's disease, the adrenal glands, located just above the kidneys, produce too little cortisol and, often, too little aldosterone. The disease affects all age groups and both male and female however is most common in the 30-50-year-old age range. The cause of the occurrence of Addison's disease includes Injury to the adrenal glands, Bleeding into the adrenal glands, infection such as tuberculosis and HIV/AIDS, and other Genetic defects. Apart from this, extreme fatigue, weight loss and decreased appetite, darkening of your skin (hyperpigmentation), nausea, diarrhea or vomiting (gastrointestinal symptoms), irritability, and depression or other behavioral symptoms are some of the major problems associated with Addison's disease.
The rising prevalence of Addison's diseases, increasing R&D activities by pharmaceutical companies in order to develop new drugs, and growing awareness regarding these diseases and treatment associated with them, are some of the major factors that drive the growth of Addison's disease market. According to the American Academy of Family Physicians Foundation, in the US, and Western Europe, the estimated prevalence of Addison disease is one in 20,000 persons. Thus, the rising prevalence of these diseases demands effective treatments and drugs to cure them, which leads to the growth of the market. However, the lack of awareness and lack of proper diagnosis acts in the early stage of the disease can become the restraining factor to the market. The development in healthcare systems, and technological innovation to decline the cost of the treatments, and FDA approvals for the novel drugs for the treatment for these diseases offer lucrative opportunities to the market during the forecast period.
The global Addison's disease market is segmented based on diagnosis, treatment, and end-user. On the basis of diagnosis, the market is segmented into laboratory testing and imaging tests. The laboratory testing by treatment segment is anticipated to grow significantly during the forecast period. Laboratory testing comprises many tests including blood test, ACTH stimulation test, insulin-induced hypoglycemia test, and other tests which are important for the treatment of these diseases. Among these tests, the ACTH stimulation test is expected to be the fastest-growing market due to the low cost of the diagnosis method. The test measures how well the adrenal glands respond to adrenocorticotropic hormone (ACTH). Thus, the rising prevalence of Addison's diseases will demand these laboratory test which in turn, further drive the market growth. By application, the global Addison's disease market is categorized into oral corticosteroid and corticosteroid injections. Similarly, based on end-user, it is divided into hospitals & clinics, and diagnostic laboratories.
Global Addison's Disease Market Share by Treatment, 2020(%)
Source: OMR global
Oral Corticosteroids holds the Major Market Share in Addison's Disease Market.
Among treatment, the oral corticosteroids held the major share in 2020, and it is projected to grow at a considerable CAGR during the forecast period. Oral corticosteroids are taken in pill or liquid form. Oral drugs are considered as the first-line treatment due to easy availability and ease of drugs administration. These medicines are prescribed by the doctor when the body does not produce certain cortisone-like hormones that are necessary to maintain good health. The use of these medicines in Addison's disease treatment owing to their effectiveness will increase its demand in the market which will further be anticipated to drive the growth of the market. The corticosteroids are of two types of Hydrocortisone, and Fludrocortisone. Both are used as a replacement treatment for adrenal glands in case of less production of natural corticosteroids.
Geographically, the global Addison's Disease market is classified into four major regions including North America (the US and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, ASEAN and Rest of Asia-Pacific), and Rest of the World (Latin America and the Middle East and Africa (MEA)). Europe is expected to hold the second-largest position in Addison's disease market. The factors attributed to the growth of this region include rising healthcare expenditure and the presence of key market players. Asia -Pacific is expected to be the fastest-growing region during the forecast period owing to the rising awareness about the disease among the population and increasing R&D activities by major market players for the development and production of new treatments and drugs.
Global Addison's Disease Market Growth, by Region 2021-2027
Source: OMR Global
North America will dominate Addison's, Disease Market.
By region, North America is projected to dominate the global Addison's disease market during the forecast period. The rising prevalence of the disease, high healthcare expenditure and well-developed health infrastructure are the major factors that propel the growth of Addison's disease market in the region. Apart from this, favorable reimbursement policies and growing government initiatives in the healthcare sector is expected to contribute to the growth of the market. The US is the major contributor with more than 90% share in the north American Addison's disease market
Market Players Outlook
The key players in the global Addison's Disease market contributing significantly by providing different types of products and increasing their geographical presence across the globe. The key players of the market include Pfizer Inc, GlaxoSmithKline plc, Lupin Pharmaceuticals, Inc., Novartis AG, Boehringer Ingelheim International GmbH., Tocris Bioscience, among others. To remain competitive in the market and to generate maximum sales revenue, the market players are adopting various strategies such as mergers & acquisitions, R&D, product launches, and geographical expansions so on.
The Report Covers
Market value data analysis of 2020 and forecast to 2027.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global Addison's disease market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.